Koup Richard A, Lamoreaux Laurie, Zarkowsky David, Bailer Robert T, King C Richter, Gall Jason G D, Brough Douglas E, Graham Barney S, Roederer Mario
Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Virol. 2009 Jun;83(12):6318-22. doi: 10.1128/JVI.00384-09. Epub 2009 Apr 1.
The magnitude and character of adenovirus serotype 5 (Ad5)-specific T cells were determined in volunteers with and without preexisting neutralizing antibodies (NAs) to Ad5 who received replication-defective Ad5 (rAd5)-based human immunodeficiency virus vaccines. There was no correlation between T-cell responses and NAs to Ad5. There was no increase in magnitude or activation state of Ad5-specific CD4(+) T cells at time points where antibodies to Ad5 and T-cell responses to the recombinant gene products could be measured. These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells.
在接受基于复制缺陷型腺病毒5型(rAd5)的人类免疫缺陷病毒疫苗的志愿者中,确定了有或没有预先存在的针对腺病毒5型(Ad5)的中和抗体(NA)的情况下,Ad5特异性T细胞的数量和特征。T细胞反应与针对Ad5的NA之间没有相关性。在可以测量针对Ad5的抗体和对重组基因产物的T细胞反应的时间点,Ad5特异性CD4(+) T细胞的数量或激活状态没有增加。这些数据表明,在E1、E3和E4区域存在缺失的基于rAd5的疫苗不会诱导载体特异性CD4(+) T细胞的明显扩增。